Want to see CVKD full AI Analyst Report?
CVKD Stock Chart & Stats
$5.22
-$1.27(-7.12%)
At close: 4:00 PM EST
$5.22
-$1.27(-7.12%)
Day’s Range― - ―
52-Week Range$2.55 - $14.64
Previous CloseN/A
Volume16.20K
Average Volume (3M)57.36K
Market Cap
$9.09M
Enterprise Value$6.58M
Total Cash (Recent Filing)$2.31M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Aug 06, 2026EPS Estimate
-1.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.63
Shares Outstanding2,868,247
10 Day Avg. Volume57,981
30 Day Avg. Volume57,363
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.94
Price to Sales (P/S)0.00
P/FCF Ratio-1.07
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.89K
Enterprise Value/Ebitda-0.55
Forecast
1Y Price Target
$29.00Price Target Upside455.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA-guided Phase 3 For CAD-1005FDA-endorsed Phase 3 design materially de-risks development path for CAD-1005 by aligning protocol, endpoints and safety expectations with regulators. A clear pivotal plan and defined trial size support efficient pathway to a potential 2029 U.S. filing and enhance partnering and commercialization optionality.
Pursuing Rare Pediatric Designation For TecarfarinTargeting orphan pediatric designation creates regulatory incentives and potential market exclusivity, enabling smaller, more efficient trials and stronger partner interest. This niche positioning leverages an underserved population and supports a differentiated commercial strategy in Asia and global rare-disease markets.
Runway Extended Via Structured Private PlacementThe structured equity financing provides immediate working capital and contingent funding while including lock-ups and issuance limits to moderate near-term dilution. Extending runway into early 2027 (potentially H2 2027) gives management time to advance pivotal programs and pursue partnerships without debt leverage.
Bears Say
Pre-revenue With Widening Losses And Cash BurnSustained pre-revenue status combined with accelerating negative operating and free cash flow (~-$11M TTM) means the business relies on external capital to fund R&D. Without revenue, margins remain undefined and ongoing burn creates persistent financing risk that affects long-term viability absent strategic partnerships or successful trial outcomes.
Sharp Erosion Of Equity BaseRapid depletion of shareholder equity signals capital erosion and increases the need for dilutive financings. A weakened equity cushion limits the company's ability to absorb development setbacks, reduces non-dilutive financing options, and can impair investor confidence during critical late-stage development windows.
Management Transitions And Role ConsolidationFrequent finance leadership changes and the CEO temporarily taking on CFO responsibilities increase operational and governance risk during a pivotal development period. This consolidation can strain oversight, slow financial strategy execution, and complicate investor and partner confidence when capital planning and trial financing are critical.
Cadrenal Therapeutics, Inc. News
CVKD FAQ
What was Cadrenal Therapeutics, Inc.’s price range in the past 12 months?
Cadrenal Therapeutics, Inc. lowest stock price was $2.55 and its highest was $14.64 in the past 12 months.
What is Cadrenal Therapeutics, Inc.’s market cap?
Cadrenal Therapeutics, Inc.’s market cap is $9.09M.
When is Cadrenal Therapeutics, Inc.’s upcoming earnings report date?
Cadrenal Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 35 days.
How were Cadrenal Therapeutics, Inc.’s earnings last quarter?
Cadrenal Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$1.04 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.04.
Is Cadrenal Therapeutics, Inc. overvalued?
According to Wall Street analysts Cadrenal Therapeutics, Inc.’s price is currently Undervalued.
Does Cadrenal Therapeutics, Inc. pay dividends?
Cadrenal Therapeutics, Inc. does not currently pay dividends.
What is Cadrenal Therapeutics, Inc.’s EPS estimate?
Cadrenal Therapeutics, Inc.’s EPS estimate is -1.55.
How many shares outstanding does Cadrenal Therapeutics, Inc. have?
Cadrenal Therapeutics, Inc. has 2,868,247 shares outstanding.
What happened to Cadrenal Therapeutics, Inc.’s price movement after its last earnings report?
Cadrenal Therapeutics, Inc. reported an EPS of -$1.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.431%.
Which hedge fund is a major shareholder of Cadrenal Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CVKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
CVKD Stock 12 Month Forecast
Average Price Target
$29.00
▲(455.56% Upside)
Technical Analysis
Daré Bioscience
―
Vyome Holdings
―
Collplant Holdings
―
Lunai Bioworks
―
Tao Synergies
―
Ownership Overview
10.41% Insiders
2.05% Mutual Funds
0.06% Other Institutional Investors
85.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---